Stockscreener 앱 받기
0.5658
37.14%
-0.3343
전일 마감가:
$0.9001
열려 있는:
$0.65
하루 거래량:
3.15M
Relative Volume:
33.92
시가총액:
$29.45M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-0.4789
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
-69.42%
1개월 성능:
-72.13%
6개월 성능:
-82.75%
1년 성능:
-85.58%
1일 변동 폭
$0.55
$0.65
1주일 범위
$0.55
$1.9424
52주 변동 폭
$0.55
$5.275
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.5658 | 29.45M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
Intensity Therapeutics sets terms for $2.35 million offering - Investing.com
Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal
Intensity Therapeutics plunges on $2.35M public offering - MSN
Why Intensity Therapeutics (INTS) Stock Is Getting Hammered - Benzinga
Intensity Therapeutics (INTS) Launches Public Offering to Raise $2.35 Million | INTS Stock News - GuruFocus
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
Intensity Therapeutics Inc (INTS)’s stock performance: a year in review - uspostnews.com
Intensity Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
INTS stock touches 52-week low at $1.49 amid market challenges - Investing.com Australia
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Intensity Therapeutics Highlights Cancer Treatment Progress - TipRanks
Is RollsRoyce (RYCEY) Stock Outpacing Its Aerospace Peers This Year? - Yahoo Finance
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Why ArcelorMittal (MT) is a Top Value Stock for the Long-Term - Yahoo Finance
Tesla Delays Launch of Cheaper, Stripped-Down Version of Model Y in US - Yahoo Finance
The Zacks Analyst Blog Highlights Affirm, StoneCo, ACI Worldwide, Coinbase Global and OppFi - Yahoo Finance
Brokers Suggest Investing in QuickLogic (QUIK): Read This Before Placing a Bet - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - Quantisnow
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Yahoo Finance
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™ - PR Newswire UK
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™. - The Manila Times
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of OD - American Heart Association Journals
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Benchmark maintains Speculative Buy on Intensity Therapeutics - Investing.com
Soft Tissue Neoplasms Treatment Market Size in 7MM is expected - openPR
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
INTENSITY THERAPEUTICS Earnings Results: $INTS Reports Quarterly Earnings - Nasdaq
Small Number of Acne Products Recalled for Problematic Levels of Benzene - 69News WFMZ-TV
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - Longview News-Journal
Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga
Bile Duct Neoplasms Treatment Market Size Report 2032 | Taewoong - openPR.com
Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas - BioSpace
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Thyroid Cancer Market Size to Reach USD 1,892.4 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients - Managed Healthcare Executive
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):